EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy

Esmée L Looman, Stephanie G C Kroeze, Jana Schaule, Mathieu Spaas, Klaus Henning Kahl, Joost J C Verhoeff, Famke L Schneiders, Oliver Blanck, Fabian Lohaus, Susanne Rogers, David Kaul, Sergi Benavente und 14 weitere

JAMA Network Open · 2026

DOI: 10.1001/jamanetworkopen.2025.53809 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Network Open, 2026. Verfasst von Esmée L Looman und 25 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Zürich, Radiation Oncology, Zürich, Switzerland. Hauptthemen laut MEDLINE: Radiosurgery, Neoplasm Metastasis, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Metastases-directed stereotactic radiotherapy (SRT) is increasingly performed in patients with metastatic or oligometastatic cancer treated with immune checkpoint inhibitors (ICIs), monoclonal antibodies (mAbs), and small-molecule drugs (SMs). However, little is known about potential interactions between SRT and biological cancer therapy (BCT).

Objective

To prospectively investigate adverse events associated with SRT combined with concurrent BCT. Design, Setting, and Participants This international, prospective, multicenter, noninterventional registry cohort study (Toxicity and Efficacy of Combined Stereotactic Radiotherapy and Systemic Targeted or Immune Therapy [TOaSTT]) was conducted between July 2017 and August 2019 with a 24-month follow-up. Patients from 27 centers whose cancer was treated with metastases-directed SRT concurrently with BCT were eligible. Analyses were performed in January 2025. Exposure Patients treated with SRT for intracranial or extracranial metastases and concurrent (within ≤30 days) BCT. Indication for treatment, decision on the radiotherapy dose and fractionation, as well as interruption of BCT, were left to the discretion of the treating clinician. Main Outcomes and Measures The primary outcome was severe (at least grade 3) adverse events of combined modality treatment, as graded by the treating physician. Overall survival (OS) and progression-free survival (PFS) were secondary end points.

Results

In total, 514 SRTs (271 cranial and 243 extracranial) concurrent with BCT were performed in 433 patients (median [IQR] age, 62 [54-70 years; 275 male [63.5%]). In 315 SRTs (61.3%) patients received ICIs, whereas in 150 SRTs (29.2%), patients received SMs and in 49 SRTs (9.5%) patients received mAbs. In 430 SRTs (83.7%), BCT had been initiated in patients before SRT, while 71 of 392 patients (18.1%) paused BCT during SRT. Severe (≥grade 3) acute adverse events were observed in 27 of 506 treatments (5.3%; 3 patients with grade 5 events), and severe late adverse events were observed in 29 of 459 patients (6.3%; 2 patients with grade 5 events). SRT with uninterrupted BCT was not associated with increased severe acute or late adverse events (odds ratio, 2.32; 95% CI, 0.87-6.22). Interruption of BCT during SRT was not associated with worse PFS and OS after correction for performance status and histologic type (hazard ratio, 0.81; 95% CI, 0.61-1.09; P = .17). Conclusions and Relevance In this cohort study of 433 patients, severe adverse events after SRT and concurrent BCT were uncommon (<10%), continuing BCT during SRT was not associated with increased risk of severe adverse events, and interrupting BCT was not associated with worse OS when correcting for patients’ performance status. These findings suggest a favorable safety profile of metastases-directed SBRT in combined modality treatment settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryNeoplasm MetastasisNeoplasmsHumansMaleFemaleAgedMiddle AgedProspective StudiesRegistriesCombined Modality TherapyAged, 80 and overImmune Checkpoint Inhibitors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • University Hospital Zürich, Radiation Oncology, Zürich, Switzerland.
  • University of Zürich, Zürich, Switzerland.
  • Cantonal Hospital Aarau, Radiation Oncology Center Mittelland, Aarau, Switzerland.
  • Ghent University Hospital, Radiation Oncology, Ghent, Belgium.
  • Universitätsklinikum Augsburg, Radiation Oncology, Augsburg, Germany.
  • University Medical Center Utrecht, Radiation Oncology, Utrecht, the Netherlands.

Zitieren

APA

Looman, E. L., Kroeze, S. G. C., Schaule, J., Spaas, M., Kahl, K. H., Verhoeff, J. J. C., Schneiders, F. L., Blanck, O., Lohaus, F., Rogers, S., Kaul, D., Benavente, S., Combs, S. E., Skazikis, G., Aninditha, K. P., Popp, I., Koppe, F. L. A., Geinitz, H., de Jaeger, K., …, & Guckenberger, M. (2026). Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.53809

Vancouver

Looman EL, Kroeze SGC, Schaule J, Spaas M, Kahl KH, Verhoeff JJC, et al. Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2025.53809

BibTeX
@article{Looman2026,
  author = {Looman, Esmée L and Kroeze, Stephanie G C and Schaule, Jana and Spaas, Mathieu and Kahl, Klaus Henning and Verhoeff, Joost J C and Schneiders, Famke L and Blanck, Oliver and Lohaus, Fabian and Rogers, Susanne and Kaul, David and Benavente, Sergi and Combs, Stephanie E and Skazikis, Georgios and Aninditha, Kynann P and Popp, Ilinca and Koppe, Friederike L A and Geinitz, Hans and de Jaeger, Katrien and Siva, Shankar and Stera, Susanne and Wittig, Andrea and Lewitzki, Victor and Eckert, Franziska and Schymalla, Markus M and Guckenberger, Matthias},
  title = {Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy},
  journal = {JAMA Network Open},
  year = {2026},
  doi = {10.1001/jamanetworkopen.2025.53809}
}
Kostenlos starten →